Sinovac Biotech Ltd represents values of innovation, integrity, and excellence in the biopharmaceutical industry. Committed to providing high-quality vaccines, Sinovac strives to improve public health and enhance the well-being of individuals worldwide. With a focus on research and development, the company aims to address various diseases and emerging threats through cutting-edge technologies and scientific advancements. Sinovac's corporate philosophy emphasizes ethical behavior, transparency, and a patient-centric approach. By fostering strong partnerships and prioritizing the needs of communities, Sinovac Biotech Ltd demonstrates its dedication to promoting global health and creating a safer future for everyone.

Sinovac Biotech Ltd is primarily present in China, where it is headquartered, as well as in other countries and regions around the world.

Sinovac Biotech Ltd, a renowned pharmaceutical company, has achieved several significant milestones over the years. Notably, Sinovac Biotech successfully developed and introduced a variety of innovative vaccines, making valuable contributions to public health. One of their major milestones was the development and commercialization of the first-ever vaccine for hepatitis A in China, known as Healive®. Furthermore, Sinovac Biotech's research and efforts led to the creation of an effective pandemic influenza vaccine, Panflu™, during the H1N1 outbreak in 2009. They also obtained the market approval for their COVID-19 vaccine, CoronaVac®, which has played a crucial role in the global fight against the ongoing pandemic. Sinovac Biotech Ltd continues to strive for excellence and make significant advancements in the field of vaccine development.

Sinovac Biotech Ltd, a leading biopharmaceutical company, was founded in 2001 in Beijing, China. With a focus on developing and commercializing vaccines, Sinovac Biotech has established itself as a trusted brand in the global healthcare industry. The company has a rich history of researching and producing high-quality vaccines, including the widely-known inactivated pandemic influenza vaccine, PANFLU, which played a significant role in combating the H1N1 virus in 2009. Sinovac Biotech has achieved several milestones, including obtaining market approvals for innovative vaccines and expanding its global reach through collaborations and partnerships. Today, Sinovac Biotech continues its commitment to public health by developing innovative vaccine solutions to protect against a wide range of infectious diseases.

The main competitors of Sinovac Biotech Ltd in the market include other leading biopharmaceutical companies, such as Pfizer Inc., Johnson & Johnson, Moderna Inc., and AstraZeneca plc.

Sinovac Biotech Ltd is primarily active in the pharmaceutical industry.

Sinovac Biotech Ltd is a leading biopharmaceutical company specializing in the research, development, production, and commercialization of vaccines to prevent infectious diseases. Their business model focuses on identifying disease targets, conducting clinical trials, manufacturing vaccines, and distributing them globally. Sinovac primarily operates by leveraging its innovative technology platforms, stringent quality control systems, and extensive industry experience. With a commitment to public health, Sinovac aims to provide safe and effective preventive vaccines to protect communities worldwide. Sinovac Biotech Ltd's business model revolves around delivering high-quality vaccines to combat infectious diseases and contributing to global healthcare efforts.

Az KGV a Sinovac Biotech esetében jelenleg nem számítható ki.

A Sinovac Biotech számára az aktuális KUV nem számítható ki.

Az AlleAktien Minőségi Score Sinovac Biotech esetében 3/10.

A Sinovac Biotech esetében jelenleg nem számítható ki az árbevétel.

A nyereséget jelenleg nem lehet kiszámítani a Sinovac Biotech számára.

Sinovac Biotech Ltd is a biopharmaceutical company specializing in the research, development, production, and marketing of vaccines. The company is headquartered in Beijing, China and has been listed on the NASDAQ since 2001. The business model of Sinovac is based on the manufacturing and sale of vaccines for various diseases such as Hepatitis A and B, influenza, polio, and COVID-19. The company is divided into three main areas: research and development, production, and marketing. The research and development department is responsible for the development of new vaccines and improving existing ones. In 2009, the company was designated by the World Health Organization (WHO) as a leading manufacturer of influenza vaccines and has consistently invested in research and development of new vaccines since then. Production takes place in modern GMP-certified facilities that meet the highest international standards. The company has the capacity to produce millions of vaccine doses per year and has a variety of production lines for different types of vaccines. Sinovac's marketing department is responsible for promoting and selling vaccines in China and worldwide. The company has a diverse customer portfolio, including governments, health organizations, and private companies. In recent years, the company has received significant attention for its work related to COVID-19. Sinovac was the first company in China to conduct clinical trials for a COVID-19 vaccine and has received approvals for several vaccines in different countries. Given the current global emergency, Sinovac has been tasked with manufacturing vaccines for a variety of countries to support the global vaccination campaign against COVID-19. In addition to the COVID-19 vaccine, Sinovac also produces vaccines for other diseases, particularly MRSA and EV71. These vaccines have already been approved in numerous countries and are used for the prevention and control of disease outbreaks. Overall, Sinovac is a leading producer of vaccines that continuously invests in the research and development of new products. With its modern production facilities and experienced team of experts, the company is well-positioned to further expand its presence in the global pharmaceutical and healthcare market.

A(z) Sinovac Biotech évente alkalommal oszt ki 0 USD összegű osztalékot.

A Sinovac Biotech esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Sinovac Biotech ISIN kódja: AGP8696W1045.

A Sinovac Biotech WKN-je 789125.

Az Sinovac Biotech tőzsdei rövidítése SVA.

Az elmúlt 12 hónapban a(z) Sinovac Biotech osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Sinovac Biotech várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) Sinovac Biotech jelenlegi osztalékhozama .

A(z) Sinovac Biotech negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Sinovac Biotech az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Sinovac Biotech a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Sinovac Biotech által 2024. 09. 22.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 09. 22.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 09. 22. időpontban történt.

2023 évben a Sinovac Biotech 0 USD összegű osztalékot fizetett ki.

Az Sinovac Biotech osztalékait USD fizeti ki.